Affiliation:
1. Department of Medicine, Division of Nephrology, San Francisco General Hospital and University of California, San Francisco, California
2. Department of Medicine, Division of Nephrology, Kaiser Foundation Hospitals & the Permanente Medical Group, Inc., Oakland, California
Abstract
Diabetic nephropathy has become the leading cause of uremia. Several lines of evidence suggest dietary factors other than protein intake have a substantial role in the progression of diabetic nephropathy to end-stage renal disease. The present investigation was initiated to evaluate whether a carbohydrate-restricted, low-iron-available, polyphenol-enriched (CR-LIPE) diet may delay and improve the outcome of diabetic nephropathy to a greater extent than standard protein restriction. To this aim, 191 diabetic patients, all with type 2 diabetes, were randomized to either CR-LIPE or standard protein restriction and the following outcomes monitored: doubling of serum creatinine, cumulative incidence of end-stage renal disease, and all cause mortality. Over a mean follow-up interval of 3.9 ± 1.8 years, serum creatinine concentration doubled in 19 patients on CR-LIPE (21%) and in 31 control subjects (39%) (P < 0.01). Renal replacement therapy or death occurred in 18 patients on CR-LIPE (20%) and in 31 control subjects (39%) (P < 0.01). These differences were independent from follow-up interval, sex, mean arterial blood pressure, HbA1c, initial renal dysfunction, and angiotensin system inhibitor use. In conclusion, CR-LIPE was 40–50% more effective than standard protein restriction in improving renal and overall survival rates.
Publisher
American Diabetes Association
Subject
Endocrinology, Diabetes and Metabolism,Internal Medicine
Reference49 articles.
1. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-enzyme inhibition on diabetic nephropathy. N Engl J Med 329: 1456–1462,1993
2. Brenner B, Cooper ME, deZeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861–869,2001
3. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345: 851–860,2001
4. Parving H-H: The impact of hypertension and antihypertensive treatment on the course and prognosis of diabetic nephropathy. J Hypertens 8: S187–S191,1990
5. Hostetter TH: Mechanisms of diabetic nephropathy. Am J Kid Dis 23: 188–192,1994
Cited by
76 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献